Age | Metabolic Syndrome
Item
men and women aged between 18 and 70 years with metabolic syndrome as defined by the international diabetes federation (idf) criteria
boolean
C0001779 (UMLS CUI [1])
C0524620 (UMLS CUI [2])
Stable body weight
Item
stable body weight for at least 3 months prior to randomization.
boolean
C0517386 (UMLS CUI [1])
Premenopausal state | Menstrual cycles regular
Item
pre-menopausal women with regular menstrual cycle (25-35 days)
boolean
C0232969 (UMLS CUI [1])
C2229012 (UMLS CUI [2])
Plasma C-reactive protein measurement
Item
plasma crp > 10 g/ml at screening
boolean
C0428493 (UMLS CUI [1])
Dyslipidemias Extreme | Hypercholesterolemia, Familial
Item
extreme dyslipidemias such as familial hypercholesterolemia
boolean
C0242339 (UMLS CUI [1,1])
C0205403 (UMLS CUI [1,2])
C0020445 (UMLS CUI [2])
Cardiovascular Disease | Coronary heart disease | Cerebrovascular Disorder | Peripheral Arterial Disease | Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Non-Insulin-Dependent | Insulin | Thiazolidinediones
Item
previous history of cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease) and type 1 or 2 diabetes or patients having received or being treated with insulin or a thiazolidinedione within the past 6 months
boolean
C0007222 (UMLS CUI [1])
C0010068 (UMLS CUI [2])
C0007820 (UMLS CUI [3])
C1704436 (UMLS CUI [4])
C0011854 (UMLS CUI [5])
C0011860 (UMLS CUI [6])
C0021641 (UMLS CUI [7])
C1257987 (UMLS CUI [8])
Pharmaceutical Preparations Affecting Inflammation | Pharmaceutical Preparations Affecting Blood lipids | Steroids | Adrenergic beta-1 Receptor Antagonists | Thiazide Diuretics | Hypolipidemic Agents | Hormone replacement therapy | Alcohol intake above recommended sensible limits
Item
subjects taking medications known to affect inflammation and blood lipids (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, hormone replacement, binging alcohol)
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0021368 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0596192 (UMLS CUI [2,3])
C0038317 (UMLS CUI [3])
C0304516 (UMLS CUI [4])
C0012802 (UMLS CUI [5])
C0086440 (UMLS CUI [6])
C0282402 (UMLS CUI [7])
C0560219 (UMLS CUI [8])
Long chain n-3 PUFA Supplements
Item
subjects taking lcn-3pufa supplements within 6 months of study onset.
boolean
C0522095 (UMLS CUI [1,1])
C0015689 (UMLS CUI [1,2])
C0242295 (UMLS CUI [1,3])